Acorda Therapeutics Stock Net Income
Acorda Therapeutics fundamentals help investors to digest information that contributes to Acorda Therapeutics' financial success or failures. It also enables traders to predict the movement of Acorda Stock. The fundamental analysis module provides a way to measure Acorda Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Acorda Therapeutics stock.
Acorda |
Acorda Therapeutics Company Net Income Analysis
Acorda Therapeutics' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Acorda Therapeutics Net Income | (252.85 M) |
Most of Acorda Therapeutics' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Acorda Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
CompetitionBased on the recorded statements, Acorda Therapeutics reported net income of (252.85 Million). This is 174.09% lower than that of the Biotechnology sector and significantly lower than that of the Health Care industry. The net income for all United States stocks is 144.28% higher than that of the company.
Acorda Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Acorda Therapeutics' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Acorda Therapeutics could also be used in its relative valuation, which is a method of valuing Acorda Therapeutics by comparing valuation metrics of similar companies.Acorda Therapeutics is currently under evaluation in net income category among its peers.
Acorda Fundamentals
Return On Equity | -0.24 | |||
Return On Asset | -0.0577 | |||
Profit Margin | (2.15) % | |||
Operating Margin | 0.04 % | |||
Current Valuation | 161.45 M | |||
Shares Outstanding | 1.24 M | |||
Shares Owned By Insiders | 0.69 % | |||
Shares Owned By Institutions | 13.22 % | |||
Number Of Shares Shorted | 8.1 K | |||
Price To Earning | 0.95 X | |||
Price To Book | 0.05 X | |||
Price To Sales | 0.01 X | |||
Revenue | 117.63 M | |||
Gross Profit | 82.43 M | |||
EBITDA | 8.4 M | |||
Net Income | (252.85 M) | |||
Cash And Equivalents | 20.7 M | |||
Cash Per Share | 0.85 X | |||
Total Debt | 190.9 M | |||
Debt To Equity | 2.56 % | |||
Current Ratio | 1.71 X | |||
Book Value Per Share | (127.17) X | |||
Cash Flow From Operations | (13.98 M) | |||
Short Ratio | 1.84 X | |||
Earnings Per Share | (203.57) X | |||
Price To Earnings To Growth | 0.51 X | |||
Target Price | 10.0 | |||
Number Of Employees | 102 | |||
Beta | 1.46 | |||
Market Capitalization | 821.03 K | |||
Total Asset | 117.75 M | |||
Retained Earnings | (1.19 B) | |||
Working Capital | (152.98 M) | |||
Current Asset | 451.32 M | |||
Current Liabilities | 90.59 M | |||
Net Asset | 117.75 M |
Pair Trading with Acorda Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Acorda Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Acorda Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Charles Schwab could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Charles Schwab when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Charles Schwab - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Charles Schwab Corp to buy it.
The correlation of Charles Schwab is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Charles Schwab moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Charles Schwab Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Charles Schwab can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Other Consideration for investing in Acorda Stock
If you are still planning to invest in Acorda Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Acorda Therapeutics' history and understand the potential risks before investing.
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Stocks Directory Find actively traded stocks across global markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |